ArticleCurrent treatment options in cardiovascular medicine2014
Platelet function testing in contemporary clinical and interventional practice.
Article in Current treatment options in cardiovascular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A substudy from the randomized PATH-PCI trial.Clinical cardiology · 2024Trial
- Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital.Journal of thrombosis and thrombolysis · 2025Article
- Clopidogrel-Mediated P2YJACC. Basic to translational science · 2024Article
- Guided vs. conventional anti-platelet therapy for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2023Article
- Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2022Review
- Antiplatelet therapy after percutaneous coronary intervention.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Article
- De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?Frontiers in cardiovascular medicine · 2022Review
- Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.Expert review of clinical pharmacology · 2021Review
- Article
- Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.BMC cardiovascular disorders · 2018Article
- Role of genetic testing in patients undergoing percutaneous coronary intervention.Expert review of clinical pharmacology · 2018Review
- Antithrombotic therapy for patients with STEMI undergoing primary PCI.Nature reviews. Cardiology · 2017Review
- High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.BMC cardiovascular disorders · 2016Article
- Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study.Journal of thrombosis and thrombolysis · 2016Observational
- Switching P2Y12-receptor inhibitors in patients with coronary artery disease.Nature reviews. Cardiology · 2016Review
- Assays of different aspects of haemostasis - what do they measure?Thrombosis journal · 2015Article
- Novel antiplatelet agents in acute coronary syndrome.Nature reviews. Cardiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementDual antiplatelet therapy with a combination of aspirin and an inhibitor of the ADP P2Y12 receptor is the recommended treatment for patients with acute coronary syndrome or who are undergoing percutaneous coronary intervention (PCI). However, patients may continue to have ischemic recurrences, including stent thrombosis, which have been linked with the well-known variability in individual response to antiplatelet therapy, and clopidogrel in particular. There are currently several assays available to measure platelet reactivity, and platelet function testing has been shown to be a valuable tool to assess the pharmacodynamic efficacy of antiplatelet drugs. Moreover, platelet reactivity has important prognostic implications, as several studies have shown an association with thrombotic and bleeding events in patients with high and low platelet reactivity, respectively. Consequently, over the past years there has been a plethora of studies investigating the optimal range of platelet reactivity associated with the highest protection against ischemic complications and the lowest risk of bleeding. Given the correlation between on-treatment platelet reactivity and outcomes, the use of platelet function testing has also been advocated to create personalized antiplatelet therapy. Several studies have been conducted in this field, but major clinical trials have failed to demonstrate a benefit of such a strategy in improving clinical outcomes. Indeed, inherent limitations of these trials may have contributed to their failure. The present manuscript provides an overview on the role of platelet function testing in contemporary clinical and interventional practice.
Identifiers
24652579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.